Differential levels of circulating progenitor cells in acute coronary syndrome patients with a first event versus patients with recurring events

Int J Cardiol. 2011 May 19;149(1):50-4. doi: 10.1016/j.ijcard.2009.11.039. Epub 2010 Jan 6.

Abstract

Objective: Pathophysiology of acute coronary syndromes in patients presenting with a first cardiac event (FCE) can be different from patients with a recurring cardiac event (RCE). We assessed inflammatory activation and circulating progenitor cells' (CPC) mobilisation in patients with a FCE versus those with RCE.

Methods: We recruited 41 patients: 18 with FCE and 23 with RCE. Peripheral blood samples were drawn at baseline and at 20 days to measure high sensitivity C-reactive protein (CRP) and to assess CD34+/133+ CPC and CD34+/KDR+ CPC by flow cytometry.

Results: CD34+/133+ cells (% number of cells per total number of cytometric events) were similar at baseline, being 0.25% (0.17-0.42%) in the FCE vs 0.23% (0.11-0.43%) in the RCE group, and increased at follow-up only in the FCE group to 0.41% (0.22-0.64%), while in the RCE group they were 0.27% (0.11-0.36%) (p=0.009 for the interaction, p=0.07 for the main effect of time). CD34+/KDR+ cells were similar at baseline in the two groups, did not significantly increase over time (p=0.2), and no differential effect of FCE vs RCE over time was seen (p=0.38). CRP levels, similar at baseline, were consistently reduced at 20 days after ACS (p=0.001), with no differential effect of FCE vs RCE pts (p=0.74). Variation from baseline to follow-up for both CD34+/133+ and CD34+/KDR+ did not correlate with either baseline CRP or delta CRP.

Conclusions: Our data demonstrate a differential CPC mobilization behavior for FCE patients compared to RCE ones, independent of inflammatory activation.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • AC133 Antigen
  • Acute Coronary Syndrome* / blood
  • Acute Coronary Syndrome* / drug therapy
  • Acute Coronary Syndrome* / pathology
  • Aged
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Antigens, CD / metabolism
  • Antigens, CD34 / metabolism
  • Benzimidazoles / therapeutic use*
  • Benzoates / therapeutic use*
  • C-Reactive Protein / metabolism
  • Female
  • Flow Cytometry
  • Glycoproteins / metabolism
  • Hematopoietic Stem Cells / cytology*
  • Hematopoietic Stem Cells / metabolism
  • Humans
  • Linear Models
  • Male
  • Middle Aged
  • Peptides / metabolism
  • Prospective Studies
  • Ramipril / therapeutic use*
  • Recurrence
  • Telmisartan

Substances

  • AC133 Antigen
  • Angiotensin-Converting Enzyme Inhibitors
  • Antigens, CD
  • Antigens, CD34
  • Benzimidazoles
  • Benzoates
  • Glycoproteins
  • Peptides
  • C-Reactive Protein
  • Ramipril
  • Telmisartan